Screen, Assess, Intervene: Nutrition and Muscle Mass in Outpatient Oncology Settings

Course Description:

Explore effective strategies to screen for malnutrition, assess muscle mass, and guide early intervention in outpatient oncology settings. This course highlights validated screening tools and evidence-based assessment methods while recognizing their practical strengths and limitations to support improved clinical outcomes. This program was originally presented as a live webinar on 17 September 2025.

Course Objectives:

• Identify validated malnutrition screening tools for use in outpatient cancer centers.
• Compare and contrast validated malnutrition screening tools for use in outpatient oncology settings, including their sensitivity, specificity, and clinical applicability.
• Describe evidence-based methods for assessing muscle mass in oncology patients, including anthropometric, imaging, and bioelectrical techniques.
• Recognize the limitations and advantages of each muscle mass assessment technique in clinical practice.

Key Takeaways:

• Routine nutrition screening should begin at diagnosis and continue every 4–8 weeks throughout treatment to identify at-risk oncology patients early, who should then be assessed by a dietitian. Successful implementation depends on involvement from the entire multidisciplinary team, as nurses and other ancillary staff typically conduct the initial screening.
• There is no single best screening tool; however, a validated tool must always be used. Screening tools include the MNA, MST, MUST, NRS-2002, NUTRISCORE, and PG-SGA SF, with the choice guided by clinic workflow, ease of use, staffing, and patient population.
• Muscle mass assessment is a critical component of malnutrition identification in patients with cancer but remains underutilized. When available, BIA, DXA, and CT are recommended technical methods; when these are not feasible, simple anthropometric measures such as calf circumference provide useful alternatives.
• Accurate diagnosis of muscle mass relies on population-, device-, and method-specific cut points. Key barriers to effective muscle mass assessment include limited clinician knowledge, lack of reference values, and equipment and time constraints, which must be addressed to support successful clinical implementation. 
• Continued progress requires increasing awareness among clinicians and clinical leadership, expanding validation of population-specific and method-specific cut points, and improving standardization of assessment procedures to help reduce the adverse functional, clinical, and cost outcomes associated with low muscle mass.

Related Questions:

• How can outpatient oncology centers determine which malnutrition screening tool is most appropriate for their patient population?
  Outpatient oncology centers should evaluate screening tools by considering both the published evidence on validity and the practical realities of their clinical environment. Trujillo et al.'s systematic review found that several screening tools, including MST, MUST, NRS-2002, NUTRISCORE, PG-SGA SF, and MNA all demonstrated validity and are recommended in ambulatory oncology settings. However, no single tool is universally preferred, as tool performance varies across studies and populations. Therefore, centers must weigh factors such as accuracy, ease of use, workflow efficiency, staffing capacity, and the characteristics of the patient population when selecting the most appropriate screening tool.
  
• What methods are recommended for assessing muscle mass in oncology patients when evaluating malnutrition risk?
  There are both technical and clinical approaches to assessing muscle mass, as recommended by the GLIM expert working group. When available and supported by trained staff, centers may use technical methods such as bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), or computed tomography (CT), all of which provide objective measurements of muscle mass. CT scans, which are often already part of routine oncology care, can be used opportunistically to assess skeletal muscle at standard anatomical landmarks. When these tools are not available or when appropriate expertise or reference values are lacking, muscle mass can still be assessed using clinical approaches, such as calf circumference, mid-upper arm circumference, and physical examination. These methods offer practical, low-cost alternatives, with calf circumference in particular showing strong correlation with skeletal muscle and being widely feasible in outpatient clinics. However, all assessment methods require attention to population, device, and disease-specific cut points for accurate interpretation.
• Why is ongoing malnutrition screening rather than a one-time assessment critical for oncology patients?
  Ongoing screening is essential because a patient’s nutritional risk can change significantly throughout cancer treatment. Nutritional status is influenced by shifting metabolic demands, treatment-related side effects, inflammation, changes in appetite, and disease progression. It is recommended that screening should begin at diagnosis and continue every 4–8 weeks, with frequency adjusted based on cancer type and treatment intensity. This ongoing approach enables clinicians to identify emerging signs of nutritional decline, such as weight loss, reduced muscle mass, or functional deterioration that might not be evident at baseline, and to ensure timely referral to a dietitian. Without regular monitoring, clinically meaningful changes may go unnoticed until they impair treatment tolerance or clinical outcomes. Continuous screening ensures that patients receive timely, targeted support throughout the course of care.